Analysis of the risk factors influencing the prognosis of orthotopic liver transplantation for hepatocellular carcinoma and summary of relevant clinical experience

National Medical Journal of China

Volumn 86, Issue 18, 2006, Pages 1232-1235

  He, Yi Feng ^a   Fan, Jia ^a   Zhou, Jian ^a   Wu, Zhi Quan ^a   Qiu, Shuang Jian ^a   Huang, Xiao Wu ^a   Yu, Yao ^a   Sun, Jian ^a   Xiao, Yong Sheng ^a   Yang, Guo Huan ^a   Song, Kang ^a   Wang, Zheng ^a   Tang, Zhao You ^a   Wang, Yu Qi ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Hepatic carcinoma; Liver transplantation; Prognosis; Recurrence; Survival

Indexed keywords

ALPHA FETOPROTEIN;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER GRADING; CANCER INVASION; CANCER RECURRENCE; CANCER SURVIVAL; DATA ANALYSIS; DIAGNOSTIC PROCEDURE; DISEASE FREE INTERVAL; EXPERIENCE; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MICROMETASTASIS; ORTHOTOPIC TRANSPLANTATION; PATIENT CARE; POSTOPERATIVE CARE; PREOPERATIVE EVALUATION; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; SURVIVAL RATE; TUMOR VOLUME; UNIVARIATE ANALYSIS; VASCULARIZATION;

ADULT; AGED; AGED, 80 AND OVER; ALPHA-FETOPROTEINS; BLOOD VESSELS; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS;

EID: 33747058503     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Schwartz M. Liver transplantation for hepatocellular carcinoma. Gastroenterology, 2004, 127: S268-276.
2. Marsh JW, Dvorchik I, Subotin M, et al. The prediction of risk of recurrence and time to recurrence of hepatocellular carcinoma after orthotopic liver transplantation: a pilot study. Hepatology, 1997, 26: 444-450.
3. Iwatsuki S, Dvorchik I, Marsh JW, et al. Liver transplantation for hepatocellular carcinoma: a proposal of a prognostic scoring system. J Am Coll Surg, 2000, 191: 389-394.
4. Ravaioli M, Ercolani G, Cescon M, et al. Liver transplantation for hepatocellular carcinoma: further considerations on selection criteria. Liver Transpl, 2004, 10: 1195-1202.
5. Lo CM, Fan ST. Liver transplantation for hepatocellular carcinoma. Br J Surg, 2004, 91: 131-133.
6. Shimoda M, Ghobrial RM, Carmody IC, et al. Predictors of survival after liver transplantation for hepatocellular carcinoma associated with hepatitis C. Liver Transpl, 2004, 10:1478-1486.
7. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med, 1996, 334: 693-699.
8. Marsh JW, Dvorchik I. Liver organ allocation for hepatocellular carcinoma: are we sure? Liver Transpl, 2003, 9: 693-696.
9. Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology, 2001, 33: 1394-1403.
10. Broelsch CE, Frilling A, Malago M. Should we expand the criteria for liver transplantation for hepatocellular carcinoma-Yes, of course! J Hepatol, 2005, 43: 569-573.
11. Chinese source. 2005, 26:136-138.
12. Chinese source. 2005, 85: 781-785.
13. Sawyers CL. Will mTOR inhibitors make it as cancer drugs? Cancer Cell, 2003, 4: 343-348.